AstraZeneca Q3 2026: revenue up 7%, oncology sales rise 17%, guidance kept
AstraZeneca reported Q3 2026 revenue of $16.21 billion, with oncology sales up 17% and full-year guidance reaffirmed. Figures as summarised by TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
AstraZeneca posted third-quarter 2026 revenue of $16.21 billion, up 7% at constant exchange rates, according to TradingView's AI-generated summary. Core earnings per share came in at $2.79 and net income at $3.12 billion. The drugmaker reaffirmed its full-year 2026 guidance.
Oncology sales climbed 17%, while Farxiga sales fell roughly 25% as generic competition arrived. The Etcamah breast cancer trial missed its primary endpoint, and a lung cancer study was halted.
why it matters
The company launched a restructuring program of up to $2 billion, targeting about $1.5 billion in annual savings by 2029, and said it does not expect a net cut in jobs. AstraZeneca also bought roughly 12% of Summit Therapeutics for $2 billion and opened a Kendall Square R&D center in Cambridge, Massachusetts. For markets, the key points are oncology growth against generic pressure on Farxiga.
market impact
Shares of AZN: reaffirmed guidance and oncology growth support, Farxiga decline weighs
- AstraZeneca shares (AZN) mixed — reaffirmed guidance and oncology growth versus the Farxiga decline and trial miss
tags
instruments
sources
- Key facts: AstraZeneca PLC Q3 $16.21B; oncology +17%; Farxiga -25%; Etcamah miss — TradingView, 31 October 2026 at 08:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗